Literature DB >> 17239045

Dysregulation of affect in multiple sclerosis: new phenomenological approach.

Yermi Harel1, Yoram Barak, Anat Achiron.   

Abstract

Disorders involving regulation of affect commonly occur in multiple sclerosis (MS). These include various clinical presentations with inconsistent definitions that lead to many nomenclatures. In order to simplify the clinical approach to dysregulation of affect (DyA) a phenomenological definition was applied that unifies and combines the current classifications. Accordingly, the prevalence of DyA was determined in MS patients and comorbidity was evaluated with psychiatric disorders. Using the Structured Clinical Interview for DSM-III-R (SCID), 651 consecutive MS patients were assessed (474 female, 177 male, mean age 43.6 years, mean disease duration 11.5 years) and it was found that the prevalence of DyA was 6.5% (n = 42). In 14 patients (33.3% of DyA patients) there was no associated psychiatric comorbidity, while in 28 patients (66.6%) there was comorbid psychopathology; 12 had been suffering from psychosis (28.6%), eight from mood disorders (19%), six from cognitive decline (14.3%) and two from personality disorder (4.7%). In 15 patients (35.7%) the DyA was ego-dystonic and in 27 patients (64.3%) the symptoms of DyA were ego-syntonic. All patients with comorbid psychosis had ego-syntonic DyA. In 14.3% of patients the DyA symptomatology preceded the appearance of MS. It is concluded that the new phenomenological definition of DyA aids in distinguishing this symptom from other psychopathologies and can serve as a tool for neurologists in defining this unique entity.

Entities:  

Mesh:

Year:  2007        PMID: 17239045     DOI: 10.1111/j.1440-1819.2007.01616.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  6 in total

Review 1.  The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review.

Authors:  Ruth Ann Marrie; Stephen Reingold; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sorensen; Gary Cutter; Nadia Reider
Journal:  Mult Scler       Date:  2015-01-12       Impact factor: 6.312

Review 2.  A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.

Authors:  Ruth Ann Marrie; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sørensen; Stephen Reingold; Gary Cutter; Nadia Reider
Journal:  Mult Scler       Date:  2015-01-26       Impact factor: 6.312

3.  Incidence and temporal trends of co-occurring personality disorder diagnoses in immune-mediated inflammatory diseases.

Authors:  C Blaney; J Sommer; R El-Gabalawy; C Bernstein; R Walld; C Hitchon; J Bolton; J Sareen; S Patten; A Singer; L Lix; A Katz; J Fisk; R A Marrie
Journal:  Epidemiol Psychiatr Sci       Date:  2020-01-09       Impact factor: 6.892

4.  Effect of disease duration on personality type in multiple sclerosis patients and healthy individual.

Authors:  Sahar Vesal; Leila Dehghani; Masoud Etemadifar; Elahe Poorazizi; Sima Akhavan; Samaneh Mazrouei; Nasim Mehdizadeh; Zahra Saraf
Journal:  Adv Biomed Res       Date:  2016-03-16

Review 5.  Neurobehavioral burden of multiple sclerosis with nanotheranostics.

Authors:  Bhasker Sriramoju; Rupinder K Kanwar; Jagat R Kanwar
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-15       Impact factor: 2.570

Review 6.  Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap.

Authors:  Dennis Walzl; Andrew J Solomon; Jon Stone
Journal:  J Neurol       Date:  2021-02-21       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.